Sort by

Send to

Choose Destination

Search results

Items: 12


Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.

Modi A, Sen S, Adachi JD, Adami S, Cortet B, Cooper AL, Geusens P, Mellström D, Weaver J, van den Bergh JP, Nguyen AM, Sajjan S; MUSIC-OS Study Group..

Osteoporos Int. 2016 Mar;27(3):1227-38. doi: 10.1007/s00198-015-3388-3.


Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators..

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342.


Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators..

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.


The public health benefit of medicines: how it has been assessed in France? The principles and results of five years' experience.

Maison P, Zanetti L, Solesse A, Bouvenot G, Massol J; ISPEP group of the French National Authority for Health..

Health Policy. 2013 Oct;112(3):273-84. doi: 10.1016/j.healthpol.2013.04.007.


[Perceptions of benign prostatic hyperplasia according to the perspective of patients and general practitioners - the Trophée study].

Lacoin F, Fourcade RO, Rouprêt M, Slama A, Le Fur C, Michel E, Sitbon A, Cotté FE.

Prog Urol. 2013 Jan;23(1):50-7. doi: 10.1016/j.purol.2012.10.003. French.


Guide de la Haute autorité de santé (HAS) : les études post-inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes.

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M; Le groupe « Intérêt de santé publique et études post-inscription » (ISPEP)..

Therapie. 2012 Sep-Oct;67(5):409-21. doi: 10.2515/therapie/2012065. French.


Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.

Neutel JM, Mancia G, Black HR, Dahlöf B, Defeo H, Ley L, Vinisko R; TEAMSTA Severe HTN Study Investigators..

J Clin Hypertens (Greenwich). 2012 Apr;14(4):206-15. doi: 10.1111/j.1751-7176.2012.00595.x.


Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Fourcade RO, Lacoin F, Rouprêt M, Slama A, Le Fur C, Michel E, Sitbon A, Cotté FE.

World J Urol. 2012 Jun;30(3):419-26. doi: 10.1007/s00345-011-0756-2.


Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators., Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.


Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators., Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317.


[Drug treatment of postmenopausal osteoporosis. What's New in 2006].

Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S, Cortet B, Costagliola D, Diebolt V, Lacoin F, Letombe B, Oberlin F, Orcel P, Ravaud P, Seret P, Thomas T, Vogel JY, Barna A, Nouyrigat E, Veyries ML, Yoldjian I.

Presse Med. 2006 Oct;35(10 Pt 2):1529-39. Review. French. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center